title: Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn's disease.
authors.forename: Walter
authors.initials: W
authors.lastname: Fries
authors.forename: Giuseppe
authors.initials: G
authors.lastname: La Malfa
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Costantino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Repici
authors.forename: Silvio
authors.initials: S
authors.lastname: Mazziotti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Navarra
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications*; D017577:Cutaneous Fistula / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D005260:Female; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab